Pharming Group (PHAR)

Pharming is positioned as a commercial rare disease player with a portfolio that combines protein replacement therapy and precision medicine. Revenue today is driven primarily by RUCONEST in acute hereditary angioedema and by Joenja in APDS, with a clear plan to expand leniolisib across broader immunologic indications and additional geographies.

• RUCONEST: recombinant C1 esterase inhibitor used for on-demand treatment of acute hereditary angioedema attacks, with a strong presence in the United States market.
• Joenja (leniolisib): oral PI3K delta inhibitor approved in the United States and several other countries for APDS in patients twelve years and older, with a growing base of paying patients and ongoing label-expansion work.
• Pipeline: expanded use of leniolisib in pediatric APDS, PIDs with immune dysregulation and common variable immunodeficiency (CVID), plus KL1333 in mitochondrial disease and potential in-licensing to add more rare disease assets.

The strategy is to leverage expertise in rare disease identification, diagnosis and long-term management, using a focused commercial footprint and targeted specialist outreach. Management is also investing in data-driven approaches, including an AI-based VUS reclassification program, to expand the number of diagnosed and treatable APDS patients worldwide.

Management snapshot – CEO Fabrice Chouraqui

• Role: Chief Executive Officer and Executive Director, appointed in early 2025 following an Extraordinary General Meeting; the prior long-serving CEO remains as strategic advisor until the end of 2025.
• Background: Former CEO-Partner at Flagship Pioneering and CEO of Cellarity, with roughly a decade of senior roles at Novartis (including President Novartis Pharmaceuticals USA) and prior commercial leadership at Bristol Myers Squibb.
• Scientific training: PharmD and advanced degrees in biomedical sciences, with an MBA from INSEAD, combining medical and business credentials.
• Focus areas (inferred from track record): commercial execution, pricing and market access, disciplined capital allocation, and deal-making in rare and specialty disease.

RUCONEST remains Pharming’s cash-generating backbone. It is an intravenous recombinant C1 esterase inhibitor used to treat acute hereditary angioedema attacks. In Q3 2025, RUCONEST delivered about 82.2 million dollars of revenue, up roughly 29 percent year-on-year, with US revenue around 81.1 million dollars and robust volume growth.

• US volume growth was approximately 24 percent in Q3 and about 28 percent over the first nine months of 2025, driven by increased patient numbers, more prescribers and higher usage in patients with more severe or frequent attacks.
• Global HAE treatments are shifting increasingly toward prophylactic therapies, which account for an estimated 85 percent of prescriptions versus about 70 percent in 2021.
• RUCONEST retains a defendable niche in the acute segment, where rapid on-demand control of severe attacks remains critical for many patients.

Pharming has decided to withdraw RUCONEST from non-US markets in order to reallocate resources toward higher-potential pipeline programmes. Non-US RUCONEST revenue represented only about 1.3 percent of Q3 sales (around 1.3 million dollars), and the company expects one-off restructuring costs around 7 million dollars in Q4 2025.

Joenja (leniolisib) is an oral, selective PI3K delta inhibitor and the first and only drug approved specifically for activated PI3K delta syndrome (APDS). In Q3 2025, Joenja generated about 15.1 million dollars of revenue, up roughly 35 percent year-on-year, and about 38.4 million dollars over the first nine months of 2025 (about 20 percent year-on-year growth).

• In the United States, around 116 APDS patients were receiving paid Joenja therapy in Q3 2025, up about 25 percent versus Q3 2024.
• Patient identification is accelerating: roughly 13 additional US patients started treatment in Q3 and about 36 in the year to date.
• Adherence in treated patients is described as consistently high, which is critical in a chronic rare disease setting.

The APDS market is inherently small, but several ongoing initiatives could expand the addressable population significantly. Pharming is working on geographic expansion, pediatric label extension, and a VUS reclassification programme that seeks to identify additional APDS patients by resolving variants of uncertain significance in the PIK3CD and PIK3R1 genes.

Analyst consensus snapshot

These analyst figures represent third-party opinions and models. They can change quickly, especially around catalysts, and should not be treated as certainties or as recommendations in themselves.

Institutional and insider ownership

Retail sentiment snapshot

• On IEX, sentiment polls for Pharming typically show around 85 percent bullish votes on a one-month horizon, rising to roughly 87 percent over a twelve-month horizon. This reflects a clearly optimistic retail base among Dutch investors.
• On Stocktwits, the PHAR symbol has on the order of nine hundred-plus watchers. This is modest in absolute terms, but enough to sustain day-to-day discussion without reaching the extremes of meme-like hype seen in some other biotech names.
• Dutch-language forums (IEX and others) feature long threads focused on Q3 numbers, the raised guidance and the January 2026 PDUFA, often with highly bullish narratives and frequent references to long-term potential of leniolisib and KL1333.

Illustrative bull framework

• FDA approves pediatric leniolisib on or close to the January 31, 2026 PDUFA date, opening the 4–11 age segment and potentially lifting Joenja revenue meaningfully in 2026.
• EMA and other geographic approvals proceed broadly on schedule, with ex-US Joenja revenue reaching material levels by 2027.
• The AI-driven VUS programme successfully reclassifies a meaningful number of variants, expanding the recognised APDS patient population much more than early estimates.
• Phase II data in PIDs/CVID are positive, supporting a rare disease franchise with potential peak sales well above APDS alone.
• RUCONEST US sales grow or stabilise at a high level despite increasing prophylactic competition.
• Under such an outcome, external models contemplate price ranges in the mid-thirties to mid-forties dollars as a bullish possibility.

Illustrative base framework

• Pediatric leniolisib is approved in the United States and roll-out progresses steadily, with moderate but not explosive growth in patient numbers.
• EMA and other regulators approve Joenja on a broadly expected timetable, with ex-US growth building gradually.
• VUS reclassification expands the APDS patient base but by less than the most optimistic scenarios.
• RUCONEST growth moderates as prophylactic competitors continue to gain share, but acute demand remains robust.
• PIDs and CVID data are mixed, with at least one positive read-out but not a fully de-risked blockbuster path yet.
• In this type of base case, some external price targets in the high twenties to low thirties dollars provide a sense of how the market could value the company if things progress broadly as expected.

Illustrative bear framework

• FDA unexpectedly rejects or significantly delays the pediatric leniolisib label expansion.
• Phase II PIDs and CVID trials fail to meet their primary endpoints, limiting leniolisib largely to APDS and reducing multi-indication upside.
• RUCONEST faces faster-than-expected erosion as prophylactic options and new competitors gain share.
• VUS reclassification proves more complex or slower than anticipated, leading to fewer newly diagnosed APDS patients than the higher-end estimates.
• Regulatory timelines at EMA and in other key markets slip by more than six months.
• Under such a bear scenario, some external models contemplate price ranges in the low-teens dollars, roughly 15–30 percent below current levels.

Key factual elements

• Q3 2025 revenue around 97.3 million dollars, up roughly 30 percent year-on-year, with RUCONEST and Joenja both growing strongly.
• Gross margin in Q3 around 92.7 percent, up from about 85 percent in Q3 2024.
• Operating profit around 15.8 million dollars in Q3 (versus 4.1 million a year earlier) and net income around 7.5 million dollars, with positive operating cash flow near 32 million dollars.
• 2025 revenue guidance raised stepwise to 365–375 million dollars versus approximately 297.2 million in 2024.
• Joenja is currently the only approved PI3K delta inhibitor for APDS; RUCONEST is a recombinant C1 esterase inhibitor for acute HAE attacks.
• FDA pediatric leniolisib sNDA is under Priority Review with a PDUFA date of January 31, 2026.
• Phase II trials for leniolisib in PIDs and CVID are ongoing, with read-outs expected in the second half of 2026.
• KL1333 is in a phase II registrational trial (FALCON) in mitochondrial disease, with read-out expected toward the end of 2027.
• Institutional ownership is very low, while reported short interest is minimal.

Key unknowns and data gaps

• Exact unit economics for Joenja (net price, gross-to-net, time from diagnosis to reimbursement and persistence) broken down by geography are not fully disclosed in public documents.
• Quantitative market-share and switching data in HAE, especially post-launch of new oral options, are not detailed; we see RUCONEST numbers but not full competitive dynamics.
• The real-world pace and scale of VUS reclassification in PIK3CD/PIK3R1 depend on external labs and evolving guidelines; internal estimates around a 20 percent conversion rate are not yet validated by multi-year clinical data.
• For KL1333, publicly available information in this context focuses on trial design and timelines, not on interim efficacy or safety results.
• Full consensus datasets (across all banks and regions) require paid terminals; here we rely on partial public information and must treat it as indicative rather than exhaustive.

Where data are missing, the right approach is to state clearly that they are missing and treat them as watch-list items for future quarterly and pipeline updates, not to fill the gaps with assumptions.